Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial

Epigenetic Mechanisms of Human Papillomavirus–Associated Head and Neck Cancer

(2015) Nicole V. J. Anayannis et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study

(2015) C. M. Pierce Campbell et al.   Cancer Prevention Research

Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—The MAM Study

(2015) Anna R. Giuliano et al.   VACCINE

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

(2015) Barbara Romanowski et al.   Human Vaccines & Immunotherapeutics

Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash

(2013) Christine M. Pierce Campbell et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels

(2013) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study

(2013) Aimée R Kreimer et al.   LANCET

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

(2013) Rolando Herrero et al.   PLoS One

Secretory immunity with special reference to the oral cavity

(2013) Per Brandtzaeg   Journal of Oral Microbiology

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals

(2012) Joseph G. Dauner et al.   MOLECULAR AND CELLULAR PROBES

Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels

(2012) Troy J. Kemp et al.   Frontiers in Oncology

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

(2011) Aimée R Kreimer et al.   LANCET ONCOLOGY

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

(2011) Anna R. Giuliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

(2010) Joseph G. Dauner et al.   VACCINE

Antibody Responses in Oral Fluid after Administration of Prophylactic Human Papillomavirus Vaccines

(2009) Ali Rowhani‐Rahbar et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Oral cancer prevention and control – The approach of the World Health Organization

(2008) Poul Erik Petersen   ORAL ONCOLOGY